~ Company signs licensing agreement with Chiesi Farmaceutici SpA to
market Atimos(R) for asthma and COPD ~
OAKVILLE, ON, June 26 /CNW/ - Nycomed Canada Inc. today announced a
licensing agreement with Chiesi Farmaceutici SpA to market Atimos(R)
(formoterol), a treatment anticipated to be indicated for asthma and Chronic
Obstructive Pulmonary Disease (COPD). In Canada, COPD is the fourth-leading
cause of death among Canadians, and recently The Lung Association reported
that COPD may affect nearly three million diagnosed and undiagnosed Canadians.
"This agreement advances Nycomed's leadership in the Canadian respiratory
market," said John Suk, president of Nycomed Canada. "Nycomed is dedicated to
providing essential medicines to Canadians with respiratory diseases.
Atimos(R) will complement our current respiratory portfolio, including
Alvesco(R) to treat mild to moderate asthma in adults and adolescents, and
Omnaris(TM) for the treatment of seasonal and perennial allergies."
Under the terms of the agreement, Nycomed Canada will be responsible for
filing and obtaining Health Canada approval for Atimos.(R), an inhaled,
long-acting bronchodilator therapy. Once approved, the company will have the
distribution, marketing, sales and promotion rights to the product in Canada.
"Atimos(R) is an extension of the Nycomed relationship with Chiesi
Farmaceutici," added Mr. Suk. "We are very pleased that Nycomed has
established this and other strong partnerships with leading pharmaceutical
companies in various therapeutic areas."
Atimos(R) is anticipated to be the first and only HFA formoterol metered
dose inhaler (MDI) available in Canada. The product is currently marketed by
Chiesi Farmaceutici SpA (under various brand names) in Italy, France, Germany,
Greece, Spain, the United Kingdom and Russia.
"We are very pleased that Atimos(R) will start registration procedures in
Canada as well," commented Alberto Chiesi, Chiesi Group president and CEO.
"Using Modulite(R) technology as a succeful platform for better drug delivery
and deposition in the lungs, Atimos(R) provides a valuable therapeutic option
for chronic respiratory diseases".
About Nycomed Canada Inc.
Nycomed Canada Inc. is the Canadian subsidiary of Nycomed GmbH; a
privately owned research-based pharmaceutical company. Ranked by sales,
Nycomed is among the 25 largest pharmaceutical companies in the world.
The Canadian head office is based in Oakville, Ontario with more than 220
employees across the country. Through its innovative products and dedicated
people, Nycomed is committed to improving the health of Canadians by providing
brand name, science-based medicines that matter.
In Canada, Nycomed markets products in the following therapeutic areas:
Nycomed Canada has been recognized as one of the 'Best Workplaces in
Canada, 2008', 'Canada's Top 100 Employers' and 'Top 50 Employers in Toronto'
For more information, please visit www.nycomed.ca. Alvesco(R) and
OMNARIS(TM) are registered trademarks of Nycomed GmbH and are used under
About Chiesi Farmaceutici S.p.A.
Founded in Parma in 1935, Chiesi Farmaceutici S.p.A. has today reached
international levels within the pharmaceutical sector in five continents with
22 direct affiliates, three manufacturing plants and three research centres.
In 2007, the Group's sales stood at 656 million Euro (+10.6% on 2006) and
its investments in research totalled 92.6 million Euro, representing 14.1% of
Chiesi Farmaceutici S.p.A has over 3,000 employees worldwide. In the
three Research & Development centres (Italy, France and the U.S.), the
workforce totals over 300 researchers, whilst those in production (Italy,
France and Brazil) total around 550 people.
Strategic alliances at both global and local level, with international
pharmaceutical groups ensure that Chiesi drugs and technology are available in
over 50 countries.
For further information: Lori Ann Horrigan, Corporate Communications,
Nycomed Canada Inc., Tel: (905) 465-4149, Cell: (416) 599-1053, Toll-free:
1-888-831-7999, ext. 4149, E-mail: LoriAnn.Horrigan@nycomed.com; Massimo
Zaninelli, Corporate Communications, Chiesi Farmaceutici S.p.A., E-mail: